MedPath

BIVALIRUDIN

These highlights do not include all the information needed to use BIVALIRUDIN FOR INJECTION safely and effectively. See full prescribing information for BIVALIRUDIN FOR INJECTION. BIVALIRUDIN for injection, for intravenous use Initial U.S. Approval: 2000

Approved
Approval ID

e574d04f-67b4-4a84-9d66-8c2d54f95120

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 23, 2023

Manufacturers
FDA

Eugia US LLC

DUNS: 968961354

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

BIVALIRUDIN

PRODUCT DETAILS

NDC Product Code55150-210
Application NumberANDA205962
Marketing CategoryC73584
Route of AdministrationINTRAVENOUS
Effective DateAugust 23, 2023
Generic NameBIVALIRUDIN

INGREDIENTS (3)

BIVALIRUDINActive
Quantity: 250 mg in 1 1
Code: TN9BEX005G
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

BIVALIRUDIN - FDA Drug Approval Details